Research programme: anti-heparanase monoclonal antibodies - InSight
Alternative Names: Anti-heparanase monoclonal antibodies - InSightLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator InSight Biopharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Heparanase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Israel
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Israel
- 06 Jun 2005 Preclinical trials in Cancer in Israel (unspecified route)